{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:15:02Z","timestamp":1779344102491,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013280","name":"Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["20240976"],"award-info":[{"award-number":["20240976"]}],"id":[{"id":"10.13039\/501100013280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12010-026-05667-0","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:35:47Z","timestamp":1774431347000},"page":"4600-4617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["METTL3-Modified FOXM1 Promotes Proliferation, Invasion, Stemness, and Immune Escape of Gastric Cancer by Influencing the Transcription of FGFR4"],"prefix":"10.1007","volume":"198","author":[{"given":"Pengqing","family":"Jiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"5667_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-025-01698-y","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen, Y., Jia, K., Xie, Y., Yuan, J., Liu, D., Jiang, L., Peng, H., Zhong, J., Li, J., Zhang, X., et al. (2025). The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. Journal of hematology & oncology, 18(1), 42.","journal-title":"Journal of hematology & oncology"},{"key":"5667_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/1477-7819-10-257","volume":"10","author":"JB Mabula","year":"2012","unstructured":"Mabula, J. B., McHembe, M. D., Koy, M., Chalya, P. L., Massaga, F., Rambau, P. F., Masalu, N., & Jaka, H. (2012). Gastric cancer at a university teaching hospital in northwestern Tanzania: a retrospective review of 232 cases. World journal of surgical oncology, 10, 257.","journal-title":"World journal of surgical oncology"},{"issue":"2","key":"5667_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.32604\/or.2024.052207","volume":"33","author":"M Santos","year":"2025","unstructured":"Santos, M., Martins, D., & Mendes, F. (2025). Immunotherapy in gastric cancer-A systematic review. Oncology research, 33(2), 263\u2013281.","journal-title":"Oncology research"},{"issue":"8","key":"5667_CR4","doi-asserted-by":"publisher","first-page":"100127","DOI":"10.1016\/j.lddd.2025.100127","volume":"22","author":"L Tao","year":"2025","unstructured":"Tao, L., Zeng, P., Yuan, X., Chen, M., Ying, J., Wei, Q., Li, J., Yu, X., & Xu, Q. (2025). The application of immunoprotein inhibitor treatment regimens based on PD-L1: A retrospective analysis after the progression of advanced gastric cancer. Letters in Drug Design & Discovery, 22(8), 100127.","journal-title":"Letters in Drug Design & Discovery"},{"issue":"2","key":"5667_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/imt-2022-0080","volume":"15","author":"YX Wu","year":"2023","unstructured":"Wu, Y. X., Zhou, X. Y., Wang, J. Q., Chen, G. M., Chen, J. X., Wang, R. C., Huang, J. Q., & Chen, J. S. (2023). Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. Immunotherapy, 15(2), 101\u2013115.","journal-title":"Immunotherapy"},{"issue":"7","key":"5667_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda, T., & Wang, Y. A. (2024). Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends in cancer, 10(7), 627\u2013642.","journal-title":"Trends in cancer"},{"key":"5667_CR7","doi-asserted-by":"crossref","unstructured":"Tao, L., Zeng, P., Yuan, X., Chen, M., Ying, J., Wei, Q., Li, J., Yu, X., & Xu, Q. (2025). The application of immunoprotein inhibitor treatment regimens based on PD-L1: a retrospective analysis after the progression of advanced gastric cancer. Letters in Drug Design & Discovery, 22(8), 100127.","DOI":"10.1016\/j.lddd.2025.100127"},{"key":"5667_CR8","doi-asserted-by":"publisher","first-page":"102608","DOI":"10.1016\/j.redox.2023.102608","volume":"60","author":"W Zhang","year":"2023","unstructured":"Zhang, W., Quan, Y., Ma, X., Zeng, L., Li, J., Chen, S., Su, M., Hong, L., Li, P., Wang, H., et al. (2023). Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy. Redox biology, 60, 102608.","journal-title":"Redox biology"},{"key":"5667_CR9","doi-asserted-by":"crossref","unstructured":"Wang, H., Xu, Q., Zhao, C., Zhu, Z., Zhu, X., Zhou, J., Zhang, S., Yang, T., Zhang, B., & Li, J. (2020). An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy. Journal for Immunotherapy of Cancer, 8(2), e000661.","DOI":"10.1136\/jitc-2020-000661"},{"issue":"3","key":"5667_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdermsci.2025.04.010","volume":"118","author":"K Liu","year":"2025","unstructured":"Liu, K., Wang, H., Dang, J., Zhu, J., Wen, Y., Chen, Z., Wang, Y., & Sun, J. (2025). Overexpression of FOXM1 drives mycosis fungoides progression by regulating the cell cycle. Journal of dermatological science, 118(3), 83\u201391.","journal-title":"Journal of dermatological science"},{"issue":"1","key":"5667_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00408-024-00773-4","volume":"203","author":"T Chen","year":"2024","unstructured":"Chen, T., Ni, M., Wang, H., Xue, F., Jiang, T., Wu, X., Li, C., Liang, S., Hong, L., & Wu, Q. (2024). The reparative effect of FOXM1 in pulmonary disease. Lung, 203(1), 1.","journal-title":"Lung"},{"issue":"22","key":"5667_CR12","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.3390\/cancers16223823","volume":"16","author":"S Dilmac","year":"2024","unstructured":"Dilmac, S., Hamurcu, Z., & Ozpolat, B. (2024). Therapeutic landscape of FOXM1 in triple-negative breast cancer and aggressive solid cancers. Cancers, 16(22), 3823.","journal-title":"Cancers"},{"issue":"3","key":"5667_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/mc.23870","volume":"64","author":"Y Chen","year":"2025","unstructured":"Chen, Y., Sun, Q., Zou, Q., Zhu, X., Wen, T., Li, X., Li, S., He, J., Wei, F., & Xie, K. (2025). FOXM1-Cx31 axis drives pancreatic cancer stem cell-like properties and chemoresistance. Molecular carcinogenesis, 64(3), 565\u2013579.","journal-title":"Molecular carcinogenesis"},{"issue":"4","key":"5667_CR14","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.curpro.2025.100029","volume":"22","author":"L Wang","year":"2025","unstructured":"Wang, L., Zhou, D., & Ou, Y. (2025). NSUN2\/FOXM1 positive feedback pathway promotes the malignant development of non-small cell lung cancer. Current Proteomics, 22(4), 100029.","journal-title":"Current Proteomics"},{"key":"5667_CR15","doi-asserted-by":"publisher","first-page":"111925","DOI":"10.1016\/j.cellsig.2025.111925","volume":"134","author":"X Liu","year":"2025","unstructured":"Liu, X., Tu, C., Yang, H., Tang, B., Ye, Y., & Wang, H. (2025). PRMT5-FOXM1 axis activates beta-catenin\/IL8 signaling to drive angiogenesis of gastric cancer. Cellular signalling, 134, 111925.","journal-title":"Cellular signalling"},{"issue":"11","key":"5667_CR16","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.3390\/ijms22115955","volume":"22","author":"NR Lee","year":"2021","unstructured":"Lee, N. R., Kim, D. Y., Jin, H., Meng, R., Chae, O. H., Kim, S. H., Park, B. H., & Kim, S. M. (2021). Inactivation of the Akt\/FOXM1 signaling pathway by panobinostat suppresses the proliferation and metastasis of gastric cancer cells. International journal of molecular sciences, 22(11), 5955.","journal-title":"International journal of molecular sciences"},{"issue":"8","key":"5667_CR17","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1007\/s00432-022-04426-y","volume":"149","author":"B Tang","year":"2023","unstructured":"Tang, B., Li, M., Xu, Y., & Li, X. (2023). N(6)-methyladenosine (m(6)A) writer KIAA1429 accelerates gastric cancer oxaliplatin chemoresistance by targeting FOXM1. Journal of cancer research and clinical oncology, 149(8), 5037\u20135045.","journal-title":"Journal of cancer research and clinical oncology"},{"issue":"10","key":"5667_CR18","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1007\/s11010-025-05322-y","volume":"480","author":"S Du","year":"2025","unstructured":"Du, S., Li, P., Liu, Y., Cai, B., Li, G., Wang, W., Yan, R., Zheng, X., & Bai, T. (2025). FOXM1 upregulation, promotes immune escape in gastric cancer through activation of Notch signaling pathway. Molecular and cellular biochemistry, 480(10), 5411\u20135427.","journal-title":"Molecular and cellular biochemistry"},{"key":"5667_CR19","doi-asserted-by":"publisher","first-page":"113759","DOI":"10.1016\/j.intimp.2024.113759","volume":"145","author":"T Hu","year":"2025","unstructured":"Hu, T., Wang, G., Wang, D., Deng, Y., & Wang, W. (2025). m6A methylation modification: Potential pathways to suppress osteosarcoma metastasis. International immunopharmacology, 145, 113759.","journal-title":"International immunopharmacology"},{"key":"5667_CR20","doi-asserted-by":"publisher","first-page":"111952","DOI":"10.1016\/j.cellsig.2025.111952","volume":"134","author":"T Xie","year":"2025","unstructured":"Xie, T., Chen, J., Sui, X., Xu, Y., Zhang, A., Zhang, Y., & Chen, J. (2025). Unraveling m6A RNA methylation: From epitranscriptomics to therapeutic frontiers in renal cell carcinoma. Cellular signalling, 134, 111952.","journal-title":"Cellular signalling"},{"issue":"1","key":"5667_CR21","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.curpro.2025.100001","volume":"22","author":"Z Wu","year":"2025","unstructured":"Wu, Z., Shen, N., Song, P., Wang, B., & Li, C. (2025). SP1-mediated WTAP exacerbates the progression of colon adenocarcinoma by m6A methylation of KLK8. Current Proteomics, 22(1), 100001.","journal-title":"Current Proteomics"},{"issue":"1","key":"5667_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10565-025-10039-1","volume":"41","author":"R Liu","year":"2025","unstructured":"Liu, R., Su, X., Yang, L., & Xiao, D. (2025). METTL3-mediated m(6)A methylation in cardiac diseases: pathogenic roles and therapeutic potential. Cell biology and toxicology, 41(1), 87.","journal-title":"Cell biology and toxicology"},{"issue":"3","key":"5667_CR23","doi-asserted-by":"publisher","first-page":"100027","DOI":"10.1016\/j.lddd.2025.100027","volume":"22","author":"Q Ren","year":"2025","unstructured":"Ren, Q., Chen, K., & Wang, L. (2025). Epigallocatechin gallate impels osteogenic differentiation of human BMSCs by targeting the METTL3\/SATB2\/Wnt\/\u03b2-catenin axis. Letters in Drug Design & Discovery, 22(3), 100027.","journal-title":"Letters in Drug Design & Discovery"},{"issue":"1","key":"5667_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-021-01447-y","volume":"21","author":"W Wan","year":"2022","unstructured":"Wan, W., Ao, X., Chen, Q., Yu, Y., Ao, L., Xing, W., Guo, W., Wu, X., Pu, C., Hu, X., et al. (2022). METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Molecular cancer, 21(1), 60.","journal-title":"Molecular cancer"},{"issue":"8","key":"5667_CR25","doi-asserted-by":"publisher","first-page":"101144","DOI":"10.1016\/j.xcrm.2023.101144","volume":"4","author":"Y Pan","year":"2023","unstructured":"Pan, Y., Chen, H., Zhang, X., Liu, W., Ding, Y., Huang, D., Zhai, J., Wei, W., Wen, J., Chen, D., et al. (2023). METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. Cell reports Medicine, 4(8), 101144.","journal-title":"Cell reports Medicine"},{"issue":"30","key":"5667_CR26","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1038\/s41388-024-03085-2","volume":"43","author":"Y Zang","year":"2024","unstructured":"Zang, Y., Tian, Z., Wang, D., Li, Y., Zhang, W., Ma, C., Liao, Z., Gao, W., Qian, L., Xu, X., et al. (2024). METTL3-mediated N(6)-methyladenosine modification of STAT5A promotes gastric cancer progression by regulating KLF4. Oncogene, 43(30), 2338\u20132354.","journal-title":"Oncogene"},{"issue":"9","key":"5667_CR27","doi-asserted-by":"publisher","first-page":"108808","DOI":"10.1016\/j.celrep.2021.108808","volume":"34","author":"TB Branigan","year":"2021","unstructured":"Branigan, T. B., Kozono, D., Schade, A. E., Deraska, P., Rivas, H. G., Sambel, L., Reavis, H. D., Shapiro, G. I., D\u2019Andrea, A. D., & DeCaprio, J. A. (2021). MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. Cell reports, 34(9), 108808.","journal-title":"Cell reports"},{"key":"5667_CR28","doi-asserted-by":"publisher","first-page":"1138524","DOI":"10.3389\/fimmu.2023.1138524","volume":"14","author":"Z Xu","year":"2023","unstructured":"Xu, Z., Pei, C., Cheng, H., Song, K., Yang, J., Li, Y., He, Y., Liang, W., Liu, B., Tan, W., et al. (2023). Comprehensive analysis of FOXM1 immune infiltrates, m6a, glycolysis and ceRNA network in human hepatocellular carcinoma. Frontiers in immunology, 14, 1138524.","journal-title":"Frontiers in immunology"},{"issue":"10","key":"5667_CR29","doi-asserted-by":"publisher","first-page":"13121","DOI":"10.1007\/s00210-025-04144-5","volume":"398","author":"F He","year":"2025","unstructured":"He, F., Liu, H., & Zhao, F. (2025). The oncogenic role of FOXM1 in hepatocellular carcinoma: molecular mechanisms, clinical significance, and therapeutic potentials. Naunyn-Schmiedeberg\u2019s archives of pharmacology, 398(10), 13121\u201313152.","journal-title":"Naunyn-Schmiedeberg\u2019s archives of pharmacology"},{"issue":"1","key":"5667_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13046-023-02872-1","volume":"42","author":"R Xu","year":"2023","unstructured":"Xu, R., Lee, Y. J., Kim, C. H., Min, G. H., Kim, Y. B., Park, J. W., Kim, D. H., Kim, J. H., & Yim, H. (2023). Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1. Journal of experimental & clinical cancer research: CR, 42(1), 302.","journal-title":"Journal of experimental & clinical cancer research: CR"},{"issue":"Pt 4","key":"5667_CR31","doi-asserted-by":"publisher","first-page":"137201","DOI":"10.1016\/j.ijbiomac.2024.137201","volume":"282","author":"SR Natarajan","year":"2024","unstructured":"Natarajan, S. R., Krishnamoorthy, R., Alshuniaber, M. A., Al-Anazi, K. M., Farah, M. A., Rajagopal, P., Palanisamy, C. P., Veeraraghavan, V. P., & Jayaraman, S. (2024). Identification of FOXM1 as a novel protein biomarker and therapeutic target for colorectal cancer progression: evidence from immune infiltration and bioinformatic analyses. International journal of biological macromolecules, 282(Pt 4), 137201.","journal-title":"International journal of biological macromolecules"},{"issue":"11","key":"5667_CR32","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1002\/iid3.727","volume":"10","author":"K Ma","year":"2022","unstructured":"Ma, K., Sun, Z., Li, X., Guo, J., Wang, Q., & Teng, M. (2022). Forkhead box M1 recruits FoxP3(+) Treg cells to induce immune escape in hilar cholangiocarcinoma. Immunity inflammation and disease, 10(11), e727.","journal-title":"Immunity inflammation and disease"},{"issue":"1","key":"5667_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41416-024-02658-y","volume":"131","author":"M Braun","year":"2024","unstructured":"Braun, M., Piasecka, D., Sadej, R., & Romanska, H. M. (2024). FGFR4-driven plasticity in breast cancer progression and resistance to therapy. British journal of cancer, 131(1), 11\u201322.","journal-title":"British journal of cancer"},{"issue":"1","key":"5667_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41419-025-07588-y","volume":"16","author":"EG Sun","year":"2025","unstructured":"Sun, E. G., Choi, J. N., Park, M. R., Kim, D. H., Sung, M., Shim, H. J., Hwang, J. E., Bae, W. K., Jung, C., Kim, Y. K., et al. (2025). FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer. Cell death & disease, 16(1), 424.","journal-title":"Cell death & disease"},{"issue":"1","key":"5667_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie, M., Lin, Z., Ji, X., Luo, X., Zhang, Z., Sun, M., Chen, X., Zhang, B., Liang, H., Liu, D., et al. (2023). FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Journal of hepatology, 79(1), 109\u2013125.","journal-title":"Journal of hepatology"},{"issue":"1","key":"5667_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12943-025-02408-5","volume":"24","author":"KJ Crawford","year":"2025","unstructured":"Crawford, K. J., Humphrey, K. S., Cortes, E., Wang, J., Kumarasamy, V., Wan, Y., Long, M. D., Feigin, M. E., Witkiewicz, A. K., Mann, K. M., et al. (2025). Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. Molecular cancer, 24(1), 208.","journal-title":"Molecular cancer"},{"key":"5667_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2022.01.067","volume":"595","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhang, X., Han, R., Wang, Z., Yang, Q., Huang, Y., & Yan, Y. (2022). BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro. Biochemical and biophysical research communications, 595, 22\u201327.","journal-title":"Biochemical and biophysical research communications"},{"key":"5667_CR38","doi-asserted-by":"publisher","first-page":"102998","DOI":"10.1016\/j.redox.2023.102998","volume":"69","author":"M Soutto","year":"2024","unstructured":"Soutto, M., Zhang, X., Bhat, N., Chen, Z., Zhu, S., Maacha, S., Genoula, M., El-Gazzaz, O., Peng, D., Lu, H., et al. (2024). Fibroblast growth factor receptor-4 mediates activation of nuclear factor erythroid 2-Related factor-2 in gastric tumorigenesis. Redox biology, 69, 102998.","journal-title":"Redox biology"},{"issue":"3","key":"5667_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10120-025-01596-9","volume":"28","author":"Y Maruyama","year":"2025","unstructured":"Maruyama, Y., Saito, M., Nakajima, S., Saito, K., Suzuki, H., Kanoda, R., Okayama, H., Hanayama, H., Sakamoto, W., Saze, Z., et al. (2025). Lenvatinib suppress FGF19-FGFR4 signaling to enhance antitumor immune response in gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 28(3), 397\u2013408.","journal-title":"Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"issue":"1","key":"5667_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","volume":"13","author":"C Zeng","year":"2020","unstructured":"Zeng, C., Huang, W., Li, Y., & Weng, H. (2020). Roles of METTL3 in cancer: mechanisms and therapeutic targeting. Journal of hematology & oncology, 13(1), 117.","journal-title":"Journal of hematology & oncology"},{"issue":"7","key":"5667_CR41","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/gutjnl-2019-319639","volume":"69","author":"Q Wang","year":"2020","unstructured":"Wang, Q., Chen, C., Ding, Q., Zhao, Y., Wang, Z., Chen, J., Jiang, Z., Zhang, Y., Xu, G., Zhang, J., et al. (2020). METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut, 69(7), 1193\u20131205.","journal-title":"Gut"},{"issue":"2","key":"5667_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3892\/ol.2022.13651","volume":"25","author":"Y Okugawa","year":"2023","unstructured":"Okugawa, Y., Toiyama, Y., Yin, C., Ruiya, M., Goel, A., Ichikawa, T., Imaoka, H., Kitajima, T., Shimura, T., Kawamura, M., et al. (2023). Prognostic potential of METTL3 expression in patients with gastric cancer. Oncology letters, 25(2), 64.","journal-title":"Oncology letters"},{"issue":"8","key":"5667_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/toxics12080573","volume":"12","author":"J Jian","year":"2024","unstructured":"Jian, J., Feng, Y., Wang, R., Li, C., Zhang, L., Ruan, Y., Luo, B., Liang, G., & Liu, T. (2024). METTL3-regulated lncRNA SNHG7 drives MNNG-induced epithelial-mesenchymal transition in gastric precancerous lesions. Toxics, 12(8), 573.","journal-title":"Toxics"},{"issue":"7","key":"5667_CR44","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/2326-6066.CIR-24-1179","volume":"13","author":"M Fang","year":"2025","unstructured":"Fang, M., Li, Y., Wang, P., Wang, Y., Wang, X., Wa, X., Zhang, Y., He, Z., Li, J., Li, L., et al. (2025). METTL3 inhibition restores PD-L1 expression and CD8\u2009+\u2009T-cell cytotoxic function in immunotherapy-treated gastric cancer. Cancer immunology research, 13(7), 1037\u20131052.","journal-title":"Cancer immunology research"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05667-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-026-05667-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05667-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:02:16Z","timestamp":1779343336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-026-05667-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5667"],"URL":"https:\/\/doi.org\/10.1007\/s12010-026-05667-0","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"6 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The procedures performed on all animals complied with the standards formulated by the Experimental Animal Ethics Committee of the Fourth Hospital of Hebei Medical University and obtained the approval of the said committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}